Blake Scheer, MD
Allergy & Immunology · Little Rock, ARNPI 1871585950
Payments from drug & device makers
Across 769 payments — averaging $105.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$42K
- AstraZeneca$20K
- CSL Behring$5K
- Pharming Healthcare, Inc.$5K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Regeneron Healthcare Solutions, Inc.$1K
- plus $6K from 31 others
What the payments were for
- Consulting fees$2,4333%
- Speaking & faculty fees$60,60975%
- Travel & lodging$2,7043%
- Food & beverage$15,29519%
- Education$1270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 177 | $42,035 |
| AstraZeneca | 71 | $20,347 |
| CSL Behring | 105 | $5,421 |
| Pharming Healthcare, Inc. | 34 | $5,000 |
| Takeda Pharmaceuticals U.S.A., Inc. | 52 | $1,144 |
| Regeneron Healthcare Solutions, Inc. | 40 | $1,083 |
| Grifols USA, LLC | 44 | $955 |
| Sanofi | 41 | $890 |
| Novartis | 35 | $767 |
| Genentech USA, Inc. | 28 | $561 |
| Pfizer | 28 | $381 |
| Kaleo, Inc. | 18 | $329 |
| Phadia US Inc. | 6 | $272 |
| ARS Pharmaceuticals Operations, Inc. | 7 | $225 |
| Biocryst US Sales Co., LLC | 8 | $180 |
| Blueprint Medicines Corporation | 4 | $176 |
| Shire North American Group Inc | 11 | $166 |
| Octapharma USA, Inc. | 3 | $125 |
| Incyte Corporation | 1 | $124 |
| Amgen | 8 | $122 |
| LEO Pharma Inc. | 6 | $115 |
| Optinose US, Inc. | 8 | $114 |
| Kedrion Biopharma, Inc. | 6 | $105 |
| Boehringer Ingelheim | 3 | $104 |
| Lilly USA, LLC | 4 | $74 |
| ADMA Biomanufacturing LLC | 2 | $43 |
| GC Biopharma USA, Inc. | 2 | $41 |
| Mylan Specialty L.p. | 2 | $40 |
| Teva Pharmaceuticals USA, Inc. | 3 | $38 |
| Bio Products Laboratory USA, Inc. | 3 | $35 |
| Alk-abello, Inc | 2 | $34 |
| Paratek Pharmaceuticals, Inc. | 2 | $31 |
| Verona Pharma, Inc. | 1 | $20 |
| USWM, LLC | 1 | $20 |
| Galderma Laboratories, L.p. | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $17 |
| Biocryst Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$81,168 in reported general payments places this provider in the 90th percentile of 26 allergy & immunology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 16 | $845,643 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $110,277 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 146 | $107,825 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $71,431 |
| Dupixent SyringeDupilumab | 13 | $48,646 |
| Breo ElliptaFluticasone/Vilanterol | 73 | $35,798 |
| SymbicortBudesonide/Formoterol Fumarate | 59 | $14,075 |
| Arnuity ElliptaFluticasone Furoate | 34 | $12,225 |
| Epinephrine | 50 | $11,336 |
| Azelastine Hcl | 196 | $5,040 |
| Fluticasone Propionate | 310 | $3,452 |
| Ipratropium Bromide | 121 | $3,266 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 107 | $3,105 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 29 | $2,846 |
| Ventolin HfaAlbuterol Sulfate | 32 | $2,201 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro, Cuvitru | $1,144 | $917,07429 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $42,035 | $155,848253 claims |
| CSL BehringHizentra | $5,421 | $110,27713 claims |
| AstraZenecaSymbicort | $20,347 | $14,07559 claims |
| Hikma Pharmaceuticals USAEpinephrine | $17 | $11,33650 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 26 allergy & immunology providers in Arkansas.
Other allergy & immunology in Little Rock
- Karl SitzLittle Rock$1.9M
- Jim IngramLittle Rock$62K
- Stacy GriffinLittle Rock$10K
- Ashley StonerLittle Rock$7K
- Kim JacksonLittle Rock$6K
- Adam PriceLittle Rock$4K
- Lori KagyLittle Rock$4K
- Gene FranceLittle Rock$2K
- Joshua KennedyLittle Rock$2K
- Meredith DilleyLittle Rock$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.